Within the kidney, AVPR1A contributes to acid–base handling via intercalated cells (Giesecke et al., 2019), and AVPR1A antagonists have demonstrated renoprotective effects in chronic kidney disease (CKD) models (Okada et al., 1995), including reduced proteinuria and vascular injury in partial‐nephrectomy, high‐salt, hypertensive rats (Okada et al., 1995), potentially via effects on the renin–angiotensin–aldosterone system and adrenal stress hormones (Lebedeva et al., 2023). This evidence concerns the gene AVPR1A and chronic kidney disease.